AI
Thursday, January 04, 2007 2:00:41 PM
RPRX
I didn't hear anything. Bastards wouldn't let me go to the meeting in person or I would have asked myself.
Given the QoL results, fibroids must have shurnk.
Overall, that was one of the most positive R&D days I've ever heard. The key result (aside from the incredible efficacy, which we already know), is that the upper bound of endometrial thickness in the UF trial was lower with both doses of Proellex than with placebo. This is in ~150 patients, so it's likely a real effect.
I didn't hear anything. Bastards wouldn't let me go to the meeting in person or I would have asked myself.
Given the QoL results, fibroids must have shurnk.
Overall, that was one of the most positive R&D days I've ever heard. The key result (aside from the incredible efficacy, which we already know), is that the upper bound of endometrial thickness in the UF trial was lower with both doses of Proellex than with placebo. This is in ~150 patients, so it's likely a real effect.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
